Skip to content

Author

Misako Nagasaka

We have 4 of 87 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

The evolving landscape of DLL3-directed Therapeutics in small cell lung cancer.

Small cell lung cancer (SCLC) remains one of the most lethal thoracic malignancies, characterized by rapid progression, early metastasis, and limited durable responses to conventional therapy. Delta-like ligand 3 (DLL3), a Notch pathway inhibitory ligand aberrantly overexpressed on the surface of approximately 70-85% o...

Vivian Tieu, Z. Arter, M. Nagasaka · 0 citations
Open access Oct 2026

20 years of cancer care in people living with HIV: Are we making progress?

86 Background: Major advances in HIV and cancer care have occurred over the past two decades, but whether outcomes for people living with HIV (PLHIV) with cancer have improved remains uncertain. We evaluated palliative care utilization, hospitalization burden, and survival across predefined calendar eras from 2...

K. A. Aldecoa, Chef Stan L. Macaraeg, Misako Nagasaka et al. · 0 citations
Clinical trial Sep 2026

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.

This study aimed to assess the efficacy and safety of ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated NSCLC whose disease progressed after third-generation EGFR tyrosine kinase inhibitor (TKI) therapy.

X. Le, A. Passaro, Yuan-Yuan Zhao et al. · 0 citations
Open access Aug 2026

XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma.

XPO1 inhibitor Eltanexor enhances the efficacy and durability of KRAS and pan-RAS inhibition in PDAC models and provides a preclinical rationale for clinically evaluating Eltanexor in combination with RAS-targeted therapies to delay or overcome adaptive resistance in KRAS-mutant PDAC.

H. Y. Khan, M. Al-Hallak, A. Aboukameel et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.